How many insider trades does FilingIQ track for KARD?

FilingIQ tracks 38 Form 4 insider transactions for KARD (Kardigan, Inc.), covering filings from Jun 17, 2026 onwards. 38 of those were filed in the last 90 days.

Are KARD insiders net buyers or net sellers?

Across the full Form 4 history for KARD, 3 transactions (8%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KARD insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KARD in?

Kardigan, Inc. (KARD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.12B.

KARD insider trading

NasdaqGM Healthcare

Kardigan, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

8% / 0%

Market cap

$2.12B

About Kardigan, Inc.

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Company website: www.kardigan.bio

KARD insider activity at a glance

FilingIQ has scored 38 insider transactions for KARD since Jun 17, 2026. The most recent filing in our index is dated Jun 22, 2026.

Across the full history, 3 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KARD insider trades is 63.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KARD trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,015

UNITED THERAPEUTICS Corp

APLS 271

Apellis Pharmaceuticals, Inc.

BLLN 211

BillionToOne, Inc.

KYMR 200

Kymera Therapeutics, Inc.

GH 199

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for KARD?: FilingIQ tracks 38 Form 4 insider transactions for KARD (Kardigan, Inc.), covering filings from Jun 17, 2026 onwards. 38 of those were filed in the last 90 days.
Are KARD insiders net buyers or net sellers?: Across the full Form 4 history for KARD, 3 transactions (8%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KARD insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KARD in?: Kardigan, Inc. (KARD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.12B.

Methodology & sources

Every KARD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.